West Pharmaceutical Services (WST) Research & Development (2009 - 2026)

West Pharmaceutical Services has disclosed Research & Development across 18 years of filings, most recently posting $15.8 million for Q1 2026.

• Research & Development for Q1 2026 came in at $15.8 million, down 3.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.8 million (up 8.85% YoY), and the FY2025 annual result was $74.3 million, up 7.53% from the prior year.
• Research & Development came in at $15.8 million for Q1 2026 at West Pharmaceutical Services, down from $21.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $21.8 million in Q4 2025 to a low of $13.6 million in Q3 2022.
• The 5-year median for Research & Development is $16.5 million (2023), against an average of $16.8 million.
• Across the five-year window, Research & Development advanced 20.59% in 2023 and decreased 7.39% in 2025, its largest moves.
• West Pharmaceutical Services' Research & Development stood at $15.9 million in 2022, then grew by 15.72% to $18.4 million in 2023, then climbed by 0.54% to $18.5 million in 2024, then advanced by 17.84% to $21.8 million in 2025, then dropped by 27.52% to $15.8 million in 2026.
• The last three Research & Development figures came in at $15.8 million (Q1 2026), $21.8 million (Q4 2025), and $17.1 million (Q3 2025), per Business Quant data.